4D-710 / 4D Molecular Therap |
| Recruiting | 1/2 | 40 | US | 4D-710 | 4D Molecular Therapeutics | Cystic Fibrosis Lung | 12/26 | 01/30 | | |
4D-125 / 4D Molecular Therap |
NCT04517149: 4D-125 in Patients With X-Linked Retinitis Pigmentosa (XLRP) |
|
|
| Active, not recruiting | 1/2 | 21 | US | 4D-125 IVT Injection, Observational | 4D Molecular Therapeutics | X-Linked Retinitis Pigmentosa | 06/26 | 05/29 | | |
4D-110 / 4D Molecular Therap, Roche |
NCT04483440: Dose Escalation Study of Intravitreal 4D-110 in Patients With Choroideremia |
|
|
| Active, not recruiting | 1 | 13 | US | 4D-110 | 4D Molecular Therapeutics | Choroideremia | 06/24 | 06/27 | | |
4D-150 / 4D Molecular Therap |
| Recruiting | 2 | 72 | US | 4D-150 IVT, Aflibercept IVT, Eylea | 4D Molecular Therapeutics | Diabetic Macular Edema, Diabetic Retinopathy | 02/28 | 07/28 | | |
| Recruiting | 1/2 | 215 | US | 4D-150 IVT, Aflibercept IVT | 4D Molecular Therapeutics | Neovascular (Wet) Age-Related Macular Degeneration | 11/25 | 11/26 | | |
4D-310 / 4D Molecular Therap |
NCT04519749: An Open-label, Phase 1/2 Trial of Gene Therapy 4D-310 in Adults With Fabry Disease |
|
|
| Active, not recruiting | 1/2 | 18 | US | 4D-310 | 4D Molecular Therapeutics | Fabry Disease | 01/26 | 06/30 | | |
NCT05629559: 4D-310 in Adults With Fabry Disease and Cardiac Involvement |
|
|
| Active, not recruiting | 1/2 | 18 | RoW | 4D-310 | 4D Molecular Therapeutics | Fabry Disease | 01/26 | 01/30 | | |
4D-725 / 4D Molecular Therap |
No trials found |
4D-175 / 4D Molecular Therap |
No trials found |